Bulevirtide is a drug for the treatment of chronic Hepatitis D infection in adults with compensated liver disease. Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.
- Mechanism
- Curator reviewed · 2 references
The sodium taurocholate co-transporting polypeptide (NTCP) serves to transport bile acids in the sodium salt form to the liver from the portal circulation. It is an important component of enterohepatic circulation. The Hepatitis D virus replicates independently within liver cells but requires the hepatitis B surface antigen in order to propagate. Hepatitis B and D viruses enter hepatocytes through the binding of NTCP (sodium/taurocholate cotransporting polypeptide) to the Hepatitis B virus preS1 surface protein domain.
Bulevirtide binds and subsequently inactivates the hepatitis B (HBV) and HDV receptors on hepatocytes. Bulevirtide blocks the NTCP binding site, subsequently blocking the entry of the viruses into cells. This prevents viral entry and replication, reducing symptoms of Hepatitis D infection.
- Primary indication
- Bulevirtide is indicated for the treatment of chronic Hepatitis D infection in HDV-RNA positive adult and pediatric patients aged 3+ years old and weighing at least 10kg with compensated liver disease.Curator reviewed · 3 structured indications
- First approval
- Canada, 2025 · United States, 2026 · European Union, 2020
- Also known as
- 915207G
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Bulevirtide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account